No KRAS mutations were found at baseline in these 31 patients, which is not surprising since BRAF and KRAS mutations are considered mutually exclusive.22 In addition, no difference in outcome could be identified between microsatellite stable and instable tumours. This evidence concerns the gene BRAF and neoplasm.